Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 5/20 | 0.40 |
| ▸ | PYGM | P11217 | 5/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7543362 | 0.78 | ALDH1A1 (0.43) | PYGLPYGMMTNR1ADPP4RIPK1 | |
| SCHEMBL2216388 | 0.77 | NPC1 (0.47) | PYGLPYGMRIPK1NPC1MAPK13 | |
| SCHEMBL11118093 | 0.76 | ALDH1A1 (0.43) | PYGLPYGMMTNR1ARIPK1 | |
| SCHEMBL4826771 | 0.73 | PTK2B (0.47) | PYGLPYGMMTNR1APTK2BRIPK1 | |
| SCHEMBL2406499 | 0.71 | HTT (0.45) | IDO1 | |
| SCHEMBL25556417 | 0.71 | NPC1 (0.47) | PYGLPYGMMTNR1ANPC1MAPK13 | |
| SCHEMBL14614572 | 0.71 | NPC1 (0.47) | PYGLPYGMMTNR1ANPC1MAPK13 | |
| SCHEMBL7792280 | 0.69 | PYGL (0.58) | PYGLPYGMMTNR1ARIPK1 | |
| SCHEMBL7516264 | 0.69 | CRBN (0.49) | — | |
| SCHEMBL4342519 | 0.69 | IDO1 (0.41) | PYGLPYGMIDO1DPP4RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022226116-A1 | GHRELIN TREATMENT OF BRAIN DYSFUNCTION DUE TO VIRAL INFECTION | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2022-10-27 | — | — | WO | disclosed |